With £60 million ($81.4 million) raised through recent share sales, the CDMO OXB has its eyes on a U.S. expansion. | The CDMO ...

After taking a $50 million hit in a patent lawsuit targeting its leukemia med Blincyto last year, Amgen has convinced a ...

FluMist has been approved since 2003, but, until last year, only for administration by a healthcare practitioner. The new nod ...

While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s | ...

After a 54% year-over-year sales increase for CGRP migraine drug Vyepti in the U.S., Lundbeck has raised its peak sales projection for the therapy in the key market. | After a 54% year-over-year sales ...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

For the first time, the FDA has approved a treatment for recurrent respiratory papillomatosis (RRP), a rare, chronic disease that causes benign tumors, most commonly in the voice box, and can force ...